Committee Constituted For “National Drugs Database”

New Delhi : The Drugs Controller General (India) Dr V. G. Somani has constituted  a Committee to have a comprehensive “National Drugs Database” vide office memorandum F. No. ED/Misc./365/2022 dated 27.10.2022 of following members:-

  1. Dr. HG Koshia, Commissioner, FDCA, Gujarat
  2. Sh. AK Pradhan, JDC (I), Convenor
  3. Dr. Pooja Gupta, Addl. Professor, AIIMS, New Delhi
  4. Dr Jerian Jose, Scientist D, ICMR, New Delhi
  5. Sh. DR Gahane, JC, FDA, Maharashtra
  6. Sh. BT Khanapure, SDC, Karnataka and
  7. Sh. Navneet Marwaha, SDC, HP

This decision is taken to have a comprehensive database of drug formulations manufactured/ marketed in the country providing detailed information on the drug, its dosage form, strength, details of manufacturer/ marketer/importer etc. This will not only empower the consumers but also for improving the monitoring mechanism for quality of drugs in circulation, across the country and uniform administration of the regulatory system.

The committee will examine the existing database available with various Authorities like States/UT Drugs Control Depts, CDSCO, various manufacturer/ marketer/importer.

The committee will give recommendations & Prepare a comprehensive “National Drugs Database” of drug formulations manufactured/ marketed in the country providing detailed information on the drug, its dosage form, strength, details of manufacturer/ marketer/importer etc.

The committee may co opt any other expert, as deemed necessary.

The committee will submit its recommendations including “National Drugs Database” in three months.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’